display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-204

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons